Therapeutic siRNA targeting the cancer cell stemness regulator PRDI-BF1 and RIZ domain zinc finger protein 14.

IF 4.4 3区综合性期刊 Q1 MULTIDISCIPLINARY SCIENCES Proceedings of the Japan Academy. Series B, Physical and Biological Sciences Pub Date : 2022-01-01 DOI:10.2183/pjab.98.017

Kohzoh Imai, Hiroaki Taniguchi

{"title":"Therapeutic siRNA targeting the cancer cell stemness regulator PRDI-BF1 and RIZ domain zinc finger protein 14.","authors":"Kohzoh Imai, Hiroaki Taniguchi","doi":"10.2183/pjab.98.017","DOIUrl":null,"url":null,"abstract":"<p><p>PRDI-BF1 and RIZ (PR) domain zinc finger protein 14 (PRDM14), first reported in 2007 to be overexpressed in breast cancer, plays an important role in breast cancer proliferation. Subsequent studies reported that PRDM14 is expressed in embryonic stem cells, primordial germ cells, and various cancers. PRDM14 was reported to confer stemness properties to cancer cells. These properties induce cancer initiation, cancer progression, therapeutic resistance, distant metastasis, and recurrence in refractory tumors. Therefore, PRDM14 may be an ideal therapeutic target for various types of tumors. Silencing PRDM14 expression using PRDM14-specific siRNA delivered through an innovative intravenous drug delivery system reduced the size of inoculated tumors, incidence of distant metastases, and increased overall survival in nude mice without causing adverse effects. Therapeutic siRNA targeting PRDM14 is now being evaluated in a human phase I clinical trial for patients with refractory breast cancer, including triple-negative breast cancer.</p>","PeriodicalId":20707,"journal":{"name":"Proceedings of the Japan Academy. Series B, Physical and Biological Sciences","volume":"98 7","pages":"325-335"},"PeriodicalIF":4.4000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/13/04/pjab-98-325.PMC9363597.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Proceedings of the Japan Academy. Series B, Physical and Biological Sciences","FirstCategoryId":"103","ListUrlMain":"https://doi.org/10.2183/pjab.98.017","RegionNum":3,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}

引用次数: 1

Abstract

PRDI-BF1 and RIZ (PR) domain zinc finger protein 14 (PRDM14), first reported in 2007 to be overexpressed in breast cancer, plays an important role in breast cancer proliferation. Subsequent studies reported that PRDM14 is expressed in embryonic stem cells, primordial germ cells, and various cancers. PRDM14 was reported to confer stemness properties to cancer cells. These properties induce cancer initiation, cancer progression, therapeutic resistance, distant metastasis, and recurrence in refractory tumors. Therefore, PRDM14 may be an ideal therapeutic target for various types of tumors. Silencing PRDM14 expression using PRDM14-specific siRNA delivered through an innovative intravenous drug delivery system reduced the size of inoculated tumors, incidence of distant metastases, and increased overall survival in nude mice without causing adverse effects. Therapeutic siRNA targeting PRDM14 is now being evaluated in a human phase I clinical trial for patients with refractory breast cancer, including triple-negative breast cancer.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

靶向癌细胞干性调节因子PRDI-BF1和RIZ结构域锌指蛋白14的治疗性siRNA。

PRDI-BF1和RIZ (PR)结构域锌指蛋白14 (PRDM14)于2007年首次报道在乳腺癌中过表达，在乳腺癌增殖中起重要作用。随后的研究报道，PRDM14在胚胎干细胞、原始生殖细胞和各种癌症中表达。据报道，PRDM14赋予癌细胞干细胞特性。在难治性肿瘤中，这些特性诱导肿瘤的发生、进展、治疗抵抗、远处转移和复发。因此，PRDM14可能是各种类型肿瘤的理想治疗靶点。通过创新的静脉给药系统，使用PRDM14特异性siRNA沉默PRDM14的表达，减少了接种肿瘤的大小、远处转移的发生率，并提高了裸鼠的总生存率，而不会产生不良反应。靶向PRDM14的治疗性siRNA目前正在一项针对难治性乳腺癌(包括三阴性乳腺癌)患者的人体I期临床试验中进行评估。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Proceedings of the Japan Academy. Series B, Physical and Biological Sciences 生物-综合性期刊

CiteScore

6.60

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： The Proceedings of the Japan Academy Ser. B (PJA-B) is a scientific publication of the Japan Academy with a 90-year history, and covers all branches of natural sciences, except for mathematics, which is covered by the PJA-A. It is published ten times a year and is distributed widely throughout the world and can be read and obtained free of charge through the world wide web.